Skip to main content

Table 1 Clinical applications of PD-1 and PD-L1 antibodies

From: Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Antibodies Dosagesa Indicationsb
Pembrolizumab 200 mg over 60 min q3 weeks Melanoma, NSCLC, HNSCC, urothelial carcinoma, Hodgkin’s lymphoma, MSI-high cancer, gastric cancer
200 mg over 60 min q3 weeks
carboplatin/pemetrexed
First line combination therapy for metastatic non-squamous NSCLC
Nivolumab 240 mg over 60 min q2 weeks Melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, MSI-high /dMMR CRC, HCC
3 mg/kg over 60 min q2 weeks Hodgkin’s lymphoma, HNSCC
Atezolizumab 1200 mg over 60 min q3 weeks Urothelial carcinoma, NSCLC
Durvalumab 10 mg/kg over 60 min q2 weeks Urothelial carcinoma
Avelumab 10 mg/kg over 60 min q2 weeks Merkel cell carcinoma, urothelial carcinoma
  1. Abbreviations: NSCLC non-small cell lung cancer, HNSCC head/neck squamous cell carcinoma, MSI microsatellite instability; dMMR deficient mismatch repair gene, CRC colorectal cancer, HCC hepatocellular carcinoma, min minute, q3w every 3 weeks
  2. aFfor pediatric dosing and for combination dosage and schedules, please refer to full prescribing information for each individual agent
  3. bFor exact indications, please refer to full prescribing information for each individual agent